| 2027-09-01in 365 d | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | 4568.TDaiichi Sankyo | Phase 2 | Solid Tumors | Recruiting |
| 2027-09-01in 365 d | REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | NVONovo Nordisk A/S | Phase 3 | Cardiovascular Disease | Active, not recruiting |
| 2027-09-01in 365 d | A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults | PFEPfizer | Phase 1 | Healthy | Recruiting |
| 2027-09-01in 365 d | PAP-NAP Device Clinical Study | RMDResMed | Not applicable | Obstructive Sleep Apnea | Not yet recruiting |
| 2027-09-02in 366 d | Pediatric Spinal Muscular Atrophy (SMA) China Registry | BIIBBiogen | — | Muscular Atrophy, Spinal | Active, not recruiting |
| 2027-09-02in 366 d | IBRX-042 In Participants With HPV-Associated Tumors | IBRXImmunityBio, Inc. | Phase 1 | HPV-Related Carcinoma | Active, not recruiting |
| 2027-09-03in 367 d | A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | NVONovo Nordisk A/S | Phase 2 | Type 2 Diabetes | Recruiting |
| 2027-09-10in 374 d | Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | SNYSanofi | Phase 3 | Pneumococcal Disease | Active, not recruiting |
| 2027-09-13in 377 d | A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults | AZNAstraZeneca | Phase 1 | Staphylococcus Aureus Bloodstream Infection | Recruiting |
| 2027-09-13in 377 d | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | SNYSanofi | Phase 1/2 | Plasma Cell Myeloma Refractory | Recruiting |
| 2027-09-15in 379 d | Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108 | NVONovo Nordisk A/S | Phase 1 | Obesity | Recruiting |
| 2027-09-17in 381 d | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus | ARWRArrowhead Pharmaceuticals | Phase 1/2 | Obesity | Recruiting |
| 2027-09-20in 384 d | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | AZNAstraZeneca | Phase 3 | Breast Cancer | Active, not recruiting |
| 2027-09-21in 385 d | Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | PFEPfizer | Phase 3 | Obesity | Active, not recruiting |
| 2027-09-22in 386 d | A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | SNYSanofi | Phase 2 | Hidradenitis Suppurativa | Recruiting |
| 2027-09-23in 387 d | Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | INCYIncyte Corporation | Phase 2 | Immune Thrombocytopenia | Recruiting |
| 2027-09-23in 387 d | A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity | NVONovo Nordisk A/S | Phase 1 | Overweight | Not yet recruiting |
| 2027-09-24in 388 d | Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | AMGNAmgen | Phase 3 | Lung Cancer | Recruiting |
| 2027-09-24in 388 d | A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | BIIBBiogen | Phase 3 | Spinal Muscular Atrophy | Active, not recruiting |
| 2027-09-24in 388 d | Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease | REGNRegeneron Pharmaceuticals | Phase 2 | Diabetic Kidney Disease (DKD) | Recruiting |
| 2027-09-26in 390 d | Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia | BMYBristol-Myers Squibb | — | Schizophrenia | Active, not recruiting |
| 2027-09-27in 391 d | A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | PFEPfizer | Phase 3 | COVID-19 | Recruiting |
| 2027-09-28in 392 d | A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | INCYIncyte Corporation | Phase 3 | Graft-Versus-Host Disease | Recruiting |
| 2027-09-28in 392 d | Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors | ONCBeOne Medicines | Phase 1 | Solid Tumors | Recruiting |
| 2027-09-28in 392 d | A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | REGNRegeneron Pharmaceuticals | Phase 2/3 | Lung Cancer | Active, not recruiting |
| 2027-09-29in 393 d | ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection | ACXPAcurx Pharmaceuticals Inc. | Phase 2 | Clostridium Difficile Infection Recurrence | Recruiting |
| 2027-09-29in 393 d | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | AMGNAmgen | Phase 3 | Obesity | Recruiting |
| 2027-09-29in 393 d | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | AMGNAmgen | Phase 3 | Obstructive Sleep Apnea | Recruiting |
| 2027-09-29in 393 d | A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight | AMGNAmgen | Phase 2 | Overweight or Obesity and Elevated Liver Fat | Recruiting |
| 2027-09-29in 393 d | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | AZNAstraZeneca | Phase 1/2 | Breast Cancer | Recruiting |
| 2027-09-30in 394 d | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | 4568.TDaiichi Sankyo | Phase 2 | Solid Tumors | Active, not recruiting |
| Sep 2027≤ 394 d | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | ABBVAbbVie | Phase 3 | Crohn's Disease | Active, not recruiting |
| Sep 2027≤ 394 d | A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting | ABBVAbbVie | — | Atopic Dermatitis | Active, not recruiting |
| Sep 2027≤ 394 d | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | ABBVAbbVie | Phase 1 | Hepatocellular Carcinoma | Recruiting |
| Sep 2027≤ 394 d | A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | ABBVAbbVie | Phase 2 | Ulcerative Colitis | Active, not recruiting |
| Sep 2027≤ 394 d | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | ABBVAbbVie | Phase 2/3 | Hypothyroidism | Recruiting |
| Sep 2027≤ 394 d | Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS) | ABBVAbbVie | — | Parkinson's Disease | Recruiting |
| Sep 2027≤ 394 d | A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | ABBVAbbVie | Phase 2 | Major Depressive Disorder | Recruiting |
| 2027-09-30in 394 d | Examination of Nociscan Impact on Discogenic Low Back Pain Surgical Outcomes | ACONAclarion | — | Discogenic Low Back Pain | Recruiting |
| Sep 2027≤ 394 d | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | AGENAgenus Inc. | Phase 2 | Colorectal Cancer | Active, not recruiting |
| Sep 2027≤ 394 d | Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects | ALKSAlkermes, Inc. | Phase 3 | Bipolar Disorder | Enrolling by invitation |
| 2027-09-30in 394 d | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | ALNYAlnylam Pharmaceuticals | Phase 1 | Hepatocellular Carcinoma | Recruiting |
| 2027-09-30in 394 d | RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | ALTAltimmune, Inc. | Phase 2 | Alcohol-associated Liver Disease | Active, not recruiting |
| 2027-09-30in 394 d | A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA | AZNAstraZeneca | — | Breast Cancer | Active, not recruiting |
| 2027-09-30in 394 d | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | AZNAstraZeneca | Phase 3 | Metastatic Castration-Sensitive Prostate Cancer | Active, not recruiting |
| 2027-09-30in 394 d | Study That Will Evaluate the Brazilian Population With COPD. | AZNAstraZeneca | — | COPD | Recruiting |
| 2027-09-30in 394 d | Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo | AZNAstraZeneca | — | COPD | Recruiting |
| 2027-09-30in 394 d | LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada | AZNAstraZeneca | — | Lung Cancer | Recruiting |
| 2027-09-30in 394 d | A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) | BIIBBiogen | Phase 1 | Muscular Atrophy, Spinal | Recruiting |
| 2027-09-30in 394 d | IC-8 Apthera IOL New Enrollment Post Approval Study | BLCOBausch & Lomb Incorporated | — | Cataract, Presbyopia, Posterior Capsule Opacification | Recruiting |
| Sep 2027≤ 394 d | A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism | BLCOBausch & Lomb Incorporated | Not applicable | Myopic Astigmatism | Not yet recruiting |
| 2027-09-30in 394 d | Immune Modulation During Palynziq® Treatment in Adults (IMPALA) | BMRNBioMarin Pharmaceutical | Phase 4 | Phenylketonuria | Recruiting |
| 2027-09-30in 394 d | A Prospective, Multicenter, Single Arm Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT in Chinese Population | BSXBoston Scientific Corporation | — | Carotid Artery Stenosis | Not yet recruiting |
| 2027-09-30in 394 d | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients | CGEMCullinan Therapeutics Inc. | Phase 1 | Acute Myeloid Leukemia | Not yet recruiting |
| Sep 2027≤ 394 d | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | CHRSCoherus Oncology, Inc. | Phase 2 | Hepatocellular Carcinoma | Active, not recruiting |
| Sep 2027≤ 394 d | A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) | CLYMClimb Bio, Inc. | Phase 1/2 | Systemic Lupus Erthematosus | Recruiting |
| Sep 2027≤ 394 d | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | CORTCorcept Therapeutics | Phase 2 | Pancreatic Cancer | Recruiting |
| Sep 2027≤ 394 d | Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | CYTKCytokinetics | Phase 3 | Heart Failure | Recruiting |
| 2027-09-30in 394 d | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | FATEFate Therapeutics | Phase 1 | Systemic Sclerosis | Recruiting |
| Sep 2027≤ 394 d | Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus | GKOSGlaukos Corporation | Phase 4 | Keratoconus | Recruiting |
| 2027-09-30in 394 d | Study of IMC-P115C in Advanced PRAME-Positive Cancers | IMCRImmunocore Ltd | Phase 1 | PRAME Positive, Cancer, HLA-A*02:01-positive | Recruiting |
| 2027-09-30in 394 d | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | INCYIncyte Corporation | Phase 2 | Pancreatic Cancer | Active, not recruiting |
| Sep 2027≤ 394 d | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) | IONSIonis Pharmaceuticals, Inc. | Phase 1 | Multiple System Atrophy | Recruiting |
| Sep 2027≤ 394 d | ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS) | IONSIonis Pharmaceuticals, Inc. | Phase 1/2 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Recruiting |
| Sep 2027≤ 394 d | A Study to Assess the Safety, Tolerability and Efficacy of ION775 | IONSIonis Pharmaceuticals, Inc. | Phase 2 | Hypertriglyceridemia, Severe Hypertriglyceridemia | Recruiting |
| Sep 2027≤ 394 d | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | IOVAIovance Biotherapeutics, Inc. | Phase 1/2 | Melanoma | Recruiting |
| 2027-09-30in 394 d | Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. | IPN.PAIpsen | — | Renal Cell Carcinoma | Active, not recruiting |
| Sep 2027≤ 394 d | A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | KARDKardigan, Inc. | Phase 2/3 | Symptomatic Genetic Dilated Cardiomyopathy | Recruiting |
| Sep 2027≤ 394 d | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | KTTAPasithea Therapeutics Corp. | Phase 1 | NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Neurofibromatosis Type 1 (NF1) | Recruiting |
| Sep 2027≤ 394 d | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | KYTXKyverna Therapeutics | Phase 2/3 | Myasthenia Gravis | Recruiting |
| Sep 2027≤ 394 d | A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | LLYEli Lilly and Company | Phase 2 | Obesity | Recruiting |
| Sep 2027≤ 394 d | [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer | LLYEli Lilly and Company | Phase 1 | Prostate Cancer | Active, not recruiting |
| Sep 2027≤ 394 d | A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | LLYEli Lilly and Company | Phase 3 | Hypertension | Active, not recruiting |
| Sep 2027≤ 394 d | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | LLYEli Lilly and Company | Phase 3 | Hypertension | Active, not recruiting |
| Sep 2027≤ 394 d | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | LLYEli Lilly and Company | Phase 3 | Hypertension | Active, not recruiting |
| Sep 2027≤ 394 d | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | LLYEli Lilly and Company | Phase 3 | Obesity | Active, not recruiting |
| Sep 2027≤ 394 d | A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy, Cancer | Recruiting |
| Sep 2027≤ 394 d | A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) | LLYEli Lilly and Company | Phase 2 | Irritable Bowel Syndrome, Diarrhea | Recruiting |
| Sep 2027≤ 394 d | A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight | LLYEli Lilly and Company | Phase 2 | Overweight | Recruiting |
| Sep 2027≤ 394 d | Clinical Course Of Disease In Participants With FA-CM | LXEOLexeo Therapeutics | — | Friedreich Ataxia, Cardiomyopathy | Recruiting |
| 2027-09-30in 394 d | THIO Sequenced With Cemiplimab in Advanced NSCLC | MAIAMaia Biotechnology | Phase 2 | Lung Cancer | Active, not recruiting |
| 2027-09-30in 394 d | A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants | MRNAModernaTX, Inc. | Phase 1 | Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | Recruiting |
| 2027-09-30in 394 d | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | ONCBeOne Medicines | Phase 1 | Solid Tumors | Recruiting |
| 2027-09-30in 394 d | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | ONCBeOne Medicines | Phase 1 | Solid Tumors | Recruiting |
| 2027-09-30in 394 d | Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants | PFEPfizer | — | Respiratory Syncytial Virus | Active, not recruiting |
| 2027-09-30in 394 d | Study of PTC844 in Participants With Active Rheumatoid Arthritis | PTCTPTC Therapeutics | Phase 2 | Rheumatoid Arthritis | Not yet recruiting |
| Sep 2027≤ 394 d | Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency | RAREUltragenyx Pharmaceutical Inc | Phase 3 | OTC Deficiency | Active, not recruiting |
| Sep 2027≤ 394 d | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | RCUSArcus Biosciences, Inc. | Phase 1 | Bladder Cancer | Active, not recruiting |
| 2027-09-30in 394 d | Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies | REGNRegeneron Pharmaceuticals | Phase 1 | Advanced Malignancies | Active, not recruiting |
| Sep 2027≤ 394 d | Long Term Follow-Up for RGX-111 | RGNXREGENXBIO Inc. | — | Mucopolysaccharidosis I | Enrolling by invitation |
| 2027-09-30in 394 d | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | RNTXRein Therapeutics | Phase 2 | Idiopathic Pulmonary Fibrosis | Recruiting |
| 2027-09-30in 394 d | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | SNYSanofi | Phase 3 | Atopic Dermatitis | Active, not recruiting |
| Sep 2027≤ 394 d | Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions | TFXTeleflex | Not applicable | Coronary Artery Disease | Recruiting |
| Sep 2027≤ 394 d | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma | TLSITriSalus Life Sciences, Inc. | Phase 1 | Locally Advanced Pancreatic Adenocarcinoma | Active, not recruiting |
| Sep 2027≤ 394 d | The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) | TRVITrevi Therapeutics | Phase 2 | Refractory Chronic Cough | Recruiting |
| Sep 2027≤ 394 d | A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) | UPBUpstream Bio Inc. | Phase 2 | Asthma | Active, not recruiting |
| 2027-09-30in 394 d | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | VNDAVanda Pharmaceuticals | Phase 3 | Motion Sickness | Active, not recruiting |
| 2027-09-30in 394 d | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | VRTXVertex Pharmaceuticals Incorporated | Phase 3 | Cystic Fibrosis | Active, not recruiting |
| Sep 2027≤ 394 d | A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | XFORX4 Pharmaceuticals | Phase 3 | Neutropenia | Recruiting |
| Sep 2027≤ 394 d | Zimmer Trabecular Metal Total Ankle PMCF | ZBHZimmer Biomet | Not applicable | Rheumatoid Arthritis | Active, not recruiting |
